Skip to content

Randomized Controlled Trial: Effect of Laryngeal Mask Airway Combined with Bronchial Blocker on Postoperative Complications and Cognitive Function in Thoracoscopic Thoracic Surgery

Effect of Laryngeal Mask Airway Combined with Bronchial Blocker on Postoperative Complications and Cognitive Function in Patients Undergoing Thoracoscopic Thoracic Surgery: A Randomized Controlled Trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600120389
Enrollment
Unknown
Registered
2026-03-13
Start date
2025-12-01
Completion date
Unknown
Last updated
2026-03-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative complications of thoracic surgery

Interventions

Experimental group:The intubation method of laryngeal mask airway combined with bronchial blocker
Control group:Double-lumen endotracheal intubation

Sponsors

Binzhou Medical University Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Age = 65 years, regardless of gender; 2. Scheduled for elective thoracoscopic surgery (lobectomy, segmentectomy); 3. ASA physical status class II–III; 4. Normal preoperative cognitive function (MMSE score = 26); 5. Written informed consent obtained from the patient and/or legal representative.

Exclusion criteria

Exclusion criteria: 1. Anticipated difficult airway (modified Mallampati grade IV, mouth opening 35 kg/m²); 3. History of neurological diseases such as cerebrovascular disease, dementia, Parkinson’s disease, etc.; 4. Severe uncontrolled gastroesophageal reflux disease or high risk of aspiration; 5. Coagulation disorders or history of immunosuppressant use; 6. Preoperative active pulmonary infection, severe COPD (FEV1% predicted < 50%), or pulmonary hypertension; 7. History of previous ipsilateral thoracic surgery or expected severe pleural adhesions; 8. Pregnant or lactating women.

Design outcomes

Primary

MeasureTime frame
Composite incidence of postoperative pulmonary complications (PPCs) within 7 days postoperatively;

Secondary

MeasureTime frame
BALF analysis: total cell count, percentage of neutrophils, concentrations of IL-6 and IL-8;Plasma biomarkers: detection of sRAGE and SP-D concentrations (specific biomarkers reflecting alveolar epithelial cell damage);

Countries

China

Contacts

Public ContactQuanyi Zhang

Department of Anesthesiology, Binzhou Medical University Hospital

zhang_quan_yi@126.com+86 189 5434 6736

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 20, 2026